MySkin
TAK-Circulator Corporation is engaged in drug development, focusing on innovative drugs for severe asthma, including antisense oligonucleotides targeting specific molecular pathways. The company collaborates with academic institutions and is involved in clinical trials and research to develop targeted therapies for difficult-to-treat asthma. It has a strong emphasis on nucleic acid medicines and biotechnological research.
Industries
Nr. of Employees
small (1-50)
Patents
Method for evaluating physical conditions, method for presenting information, and method for screening for substance capable of improving or preventing physical conditions
US-11802310-B2
View DetailsNucleic acid inhibiting expression of the MEX3B gene, MEX3B gene expression inhibitor, method for inhibiting MEX3B gene expression, and prophylactic or therapeutic agent for disease caused by MEX3B gene expression
US-11312956-B2
View DetailsMethod for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5
US-11279935-B2
View Details
Method for evaluating physical conditions, method for presenting information, and method for screening for substance capable of improving or preventing physical conditions
US-11802310-B2
View DetailsNucleic acid inhibiting expression of the MEX3B gene, MEX3B gene expression inhibitor, method for inhibiting MEX3B gene expression, and prophylactic or therapeutic agent for disease caused by MEX3B gene expression
US-11312956-B2
View DetailsMethod for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5
US-11279935-B2
View DetailsProducts
Gapmer‑type antisense oligonucleotide targeting Mex3B for steroid‑resistant severe asthma (inhalation)
Clinical‑stage antisense oligonucleotide therapeutic designed to reduce airway inflammation by targeting the RNA‑binding protein Mex3B; formulated as a liquid for nebulizer/inhalation administration. Demonstrated preclinical efficacy in eosinophilic and neutrophilic airway inflammation models; completed Phase I and registered exploratory clinical studies.
真菌叢ITS解析
rRNA遺伝子間のITS領域と呼ばれる配列をターゲットに解読を行い、16S rRNAを持たない真菌も含めた種類と存在比率を解析するサービス。
アクネ菌タイピング解析
皮膚状態に大きく関わるアクネ菌の種類（株レベル）を分類する特化型解析サービス。
細菌叢16S rRNA 遺伝子解析
全ての細菌が持っている16S rRNA遺伝子をターゲットに解読を行い、細菌叢に含まれる細菌の種類と存在比率を測定するメタゲノム解析サービス。
MySkin®キット
皮膚の細菌叢解析およびサンプリングを行うためのキット。テープを用いた簡単な操作で、優れた定量性と高い保存性を実現しています。
頭皮用キット
頭皮の皮膚細菌叢解析を行うための専用サンプリングキット。
Gapmer‑type antisense oligonucleotide targeting Mex3B for steroid‑resistant severe asthma (inhalation)
Clinical‑stage antisense oligonucleotide therapeutic designed to reduce airway inflammation by targeting the RNA‑binding protein Mex3B; formulated as a liquid for nebulizer/inhalation administration. Demonstrated preclinical efficacy in eosinophilic and neutrophilic airway inflammation models; completed Phase I and registered exploratory clinical studies.
真菌叢ITS解析
rRNA遺伝子間のITS領域と呼ばれる配列をターゲットに解読を行い、16S rRNAを持たない真菌も含めた種類と存在比率を解析するサービス。
アクネ菌タイピング解析
皮膚状態に大きく関わるアクネ菌の種類（株レベル）を分類する特化型解析サービス。
細菌叢16S rRNA 遺伝子解析
全ての細菌が持っている16S rRNA遺伝子をターゲットに解読を行い、細菌叢に含まれる細菌の種類と存在比率を測定するメタゲノム解析サービス。
MySkin®キット
皮膚の細菌叢解析およびサンプリングを行うためのキット。テープを用いた簡単な操作で、優れた定量性と高い保存性を実現しています。
頭皮用キット
頭皮の皮膚細菌叢解析を行うための専用サンプリングキット。
Services
Outsourced execution and management of preclinical efficacy studies in animal models through contract research organizations.
Coordination with a chemical manufacturer to produce GMP‑grade oligonucleotide active pharmaceutical ingredient for clinical trials.
Support for registration and conduct of early clinical trials, including public trial registry entries and study completion reporting.
Analysis methods and educational materials related to skin and fungal microbiome profiling (16S rRNA, ITS), with applied interpretation for skin health.
Outsourced execution and management of preclinical efficacy studies in animal models through contract research organizations.
Coordination with a chemical manufacturer to produce GMP‑grade oligonucleotide active pharmaceutical ingredient for clinical trials.
Support for registration and conduct of early clinical trials, including public trial registry entries and study completion reporting.
Analysis methods and educational materials related to skin and fungal microbiome profiling (16S rRNA, ITS), with applied interpretation for skin health.
Expertise Areas
- Oligonucleotide therapeutics development
- Inhalation drug delivery
- Preclinical pharmacology and efficacy testing
- Clinical trial management and early‑phase studies
Key Technologies
- Gapmer antisense oligonucleotides
- Inhalation nebulizer delivery
- Next‑generation sequencing (NGS) for 16S rRNA profiling
- ITS / D1-D2 sequencing for fungal profiling